UNSPSC 51102869: Oxytetracycline/phenazopyridine/sulfamethizole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.

UNSPSC 51102869 Oxytetracycline/phenazopyridine/sulfamethizole is a Commodity code that covers pharmaceutical products used in state and local health initiatives, though recent solicitation activity under this specific code designation shows limited direct alignment with the code's nominal scope. State and local health departments and county health authorities solicit pharmaceutical supplies through cooperative purchasing vehicles and competitive bidding processes, typically via piggyback awards and invitation-for-bid notices. The work involves sourcing, warehousing, and delivering prescription medications and public-health supplies to support community health programs, with contracts structured around fixed-term awards with renewal options and quarterly or as-needed delivery schedules.

Recent activity centers on Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets under Bid Number 26-482DPH-PREPD-B-53392 via invitation-for-bid process, with a 12-month initial term and two optional renewal years. Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a July 26, 2026 response deadline for quarterly delivery to the Seminole County Community Health Building in Sanford. Note that recent opportunities tagged to this code reflect broader pharmaceutical procurement activity — the actual products being procured (doxycycline, ciprofloxacin, naloxone, and deactivation systems) do not align precisely with the code's technical name, suggesting the code may be used as a general pharmaceutical-services catch-all rather than for the specific oxytetracycline combination it nominally describes.